Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital

O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status has been considered a prognostic factor in newly diagnosed glioblastoma (GBM). In this study, we evaluated the prognostic and predictive value of MGMT promoter methylation in patients with glioblastoma in Donostia Hospital....

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Sci Rep
Päätekijät: Egaña, Larraitz, Auzmendi-Iriarte, Jaione, Andermatten, Joaquin, Villanua, Jorge, Ruiz, Irune, Elua-Pinin, Alejandro, Aldaz, Paula, Querejeta, Arrate, Sarasqueta, Cristina, Zubia, Felix, Matheu, Ander, Samprón, Nicolas
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7595088/
https://ncbi.nlm.nih.gov/pubmed/33116181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-75477-9
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia